Recurrent Atrial Fibrillation

University of Cincinnati1 enrolled

Overview

This study will evaluate the recurrence rates of atrial fibrillation that develops in the hospital following non cardiac procedures or surgeries or acute medical illnesses.

Eligible individuals with no previous history of atrial fibrillation or flutter who develop a limited episode of atrial fibrillation during a hospital stay for an acute medical illness or non-cardiothoracic surgery or procedure. Patients will be monitored for a period of 1 month using Medtronic SEEQ monitors for recurrence. Subjects will self assign to wear the SEEQ monitor or standard of care. Individuals with implanted cardiac devices capable of detecting atrial fibrillation will also be included.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SCREENING

Masking

NONE

Enrollment

Conditions

Atrial Fibrillation

Interventions

SEEQ monitorDEVICE

An external cardiac rhythm monitor

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Development of atrial fibrillation or flutter during a hospital stay following a non-cardiac procedure or acute medical illness * CHADS2VASc score of 2 or more Exclusion Criteria: * Prior history of atrial fibrillation of flutter * Requiring ventilator support or in shock * Acute decompensated heart failure or EF =/\< 40% * Greater than mild valvular heart disease * Other structural heart disease such as more than mild LVH, constrictive or restrictive cardiomyopathy * Hyperthyroidism uncontrolled at the time of diagnosis if known * Pulmonary embolism that requires thrombolysis or resulted in shock * Use of antiarrhythmic drugs (class I or III) at the time of discharge * Cardiothoracic surgery in the last 6 months

Locations (1)

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Outcomes

Primary Outcomes

Recurrence of atrial fibrillation

The rate of recurrence of atrial fibrillation will be compared to the recurrence noted in the standard of care arm.

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.